TWILIGHT-HF Subgroup Analysis Score

Exploratory TWILIGHT-HF Subgroup Analysis Score: Explanation and context The TWILIGHT randomized trial tested whether, among high-risk patients who had completed 3 months of dual antiplatelet therapy after PCI, stopping aspirin and continuing ticagrelor monotherapy reduced clinically relevant bleeding without increasing ischemic events. The trial found a lower rate of BARC 2/3/5 bleeding with ticagrelor monotherapy versus ticagrelor plus aspirin, with ischemic outcomes noninferior across the whole study population. Subgroup analyses (preplanned and post-hoc) assessed consistency of the bleeding/ischemic effects across groups defined by age, sex, diabetes, ACS status and other baseline variables.

This tool aggregates a small set of those subgroup variables into a transparent point count to illustrate relative subgroup burden; it is not a replication of a published predictive score and does not produce validated absolute risk predictions.